AMENDMENT NO. 1 TO THIRD AMENDED AND RESTATED LIMITED LIABILITY COMPANY AGREEMENT OF AMNEAL PHARMACEUTICALS LLCLimited Liability Company Agreement • March 1st, 2019 • Amneal Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This Amendment No. 1 to the Third Amended and Restated Limited Liability Company Agreement of Amneal Pharmaceuticals LLC (this “Amendment”), dated as of February 14, 2019, with effect as of May 4, 2018, is entered into by and among Amneal Pharmaceuticals LLC (the “Company”), the Manager and the Members set forth on the signature pages hereto.
SEPARATION AGREEMENTSeparation Agreement • March 1st, 2019 • Amneal Pharmaceuticals, Inc. • Pharmaceutical preparations • New Jersey
This Separation Agreement (the "Agreement") is entered into between Sheldon Hirt ("Executive" ) and Amneal Pharmaceuticals, Inc., a Delaware corporation (the "Company" and, together with Executive, the "Parties" ) and, unless revoked in accordance with Section 5, shall become effective as of the eighth day after the day on which Executive signs this Agreement (the " Effective Date"), which, for the avoidance of doubt, shall not be prior to the Separation Date (as defined below). This Agreement is entered into with reference to the following facts:
PERFORMANCE RESTRICTED STOCK UNIT AGREEMENTPerformance Restricted Stock Unit Agreement • March 1st, 2019 • Amneal Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
Amneal Pharmaceuticals, Inc., a Delaware corporation (the “Company”), pursuant to its 2018 Incentive Award Plan, as amended from time to time (the “Plan”), hereby grants to the holder listed below (“Participant”) the number of Performance Restricted Stock Units set forth below (the “PSUs”). The PSUs are subject to the terms and conditions set forth in this Performance Restricted Stock Unit Grant Notice (the “Grant Notice”), the Plan, the Performance Restricted Stock Unit Agreement attached as Exhibit A (the “Agreement”) and the special provisions for Participant’s country of residence, if any, attached hereto as Exhibit B (the “Foreign Appendix”), each of which is incorporated into this Grant Notice by reference. Unless otherwise defined herein, the terms defined in the Plan shall have the same defined meanings in this Grant Notice and the Agreement.
SEPARATION AGREEMENTSeparation Agreement • March 1st, 2019 • Amneal Pharmaceuticals, Inc. • Pharmaceutical preparations • New Jersey
This Separation Agreement (the “Agreement”) is entered into between Bryan M. Reasons (“Executive”) and Amneal Pharmaceuticals, Inc., a Delaware corporation (the “Company” and, together with Executive, the “Parties”) and, unless revoked in accordance with Section 5(d), shall become effective as of the eighth day after the day on which Executive signs this Agreement (the “Effective Date”). This Agreement is entered into with reference to the following facts:
